SBRT Boost in Prostate Cancer: Progress Made, Questions Remain
This article relates to:
-
In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer
- The Prostate
- First Published online: July 28, 2025
Corresponding Author
Cem Onal
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
Correspondence: Cem Onal ([email protected])
Search for more papers by this authorAysenur Elmali
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorBirhan Demirhan
Division of Radiation Oncology, Iskenderun Gelisim Hospital, İskenderun, Hatay, Turkey
Search for more papers by this authorOzan Cem Guler
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
Search for more papers by this authorCorresponding Author
Cem Onal
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
Correspondence: Cem Onal ([email protected])
Search for more papers by this authorAysenur Elmali
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorBirhan Demirhan
Division of Radiation Oncology, Iskenderun Gelisim Hospital, İskenderun, Hatay, Turkey
Search for more papers by this authorOzan Cem Guler
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
Search for more papers by this authorOpen Research
Data Availability Statement
The authors have nothing to report.
References
- 1A. Gouveia, A. Mesci, N. Isfahanian, et al., “Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer,” Prostate, ahead of print, April 27, 2025, https://doi.org/10.1002/pros.24905.
- 2A. U. Kishan, A. Dang, A. J. Katz, et al., “Long-Term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer,” JAMA Network Open 2, no. 2 (2019): e188006.
- 3P. Fransson, P. Nilsson, A. Gunnlaugsson, et al., “Ultra-Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer (HYPO-RT-PC): Patient-Reported Quality-of-Life Outcomes of a Randomised, Controlled, Non-Inferiority, Phase 3 Trial,” Lancet Oncology 22, no. 2 (2021): 235–245.
- 4C. Onal, G. Erbay, O. C. Guler, C. Yavas, and E. Oymak, “Treatment Outcomes of Simultaneous Integrated Boost to Intraprostatic Lesions With External Beam Radiotherapy in Localized Prostate Cancer Patients,” Prostate 83, no. 12 (2023): 1158–1166.
- 5C. Onal, O. C. Guler, G. Erbay, B. Demirhan, A. Elmali, and M. Yavuz, “Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer,” Prostate 85, no. 8 (2025): 805–813.
- 6N. Mottet, R. C. N. van den Bergh, E. Briers, et al., “EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment With Curative Intent,” European Urology 79, no. 2 (2021): 243–262.
- 7E. Basch, A. M. Deal, M. G. Kris, et al., “Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial,” Journal of Clinical Oncology 34, no. 6 (2016): 557–565.
- 8C. Onal, O. C. Guler, G. Erbay, and A. Elmali, “The Effect of Dose-Escalation Radiotherapy With Simultaneous-Integrated-Boost on the Use of Short-Term Androgen Deprivation Therapy in Patients With Intermediate Risk Prostate Cancer,” Prostate 84, no. 8 (2024): 763–771.
